Our Companies
Exosomm is a FoodTech company supported by Galil Ofek Innovation. Inspired by the virtues of mother milk and its unique health properties, the company is creating patent-based nutritional solutions with naturally isolated milk exosomes that are beneficial in cases of inflammation, infection, and cancer.
The Need
IBD, Inflammatory Bowel Diseases, includes Crohn’s disease and ulcerative colitis, both incurable chronic inflammatory diseases. IBD patients suffer from abdominal pain, bloody diarrhea, prolonged fevers, decreased appetites, and weigh less as a consequence. They are at high risk for bowel cancer and despite all current treatments, a large number of patients will not go into remission, 50% will require surgical intervention, and will suffer from low quality of life. Moreover, current nutritional therapies are only partially effective.
Exosomm’s Solution
The company’s first product is a food formula with a patented active anti-inflammatory ingredient. The food formula is designed to reduce inflammation scores and prolong periods of remission in patients with IBD.
With proven isolation protocols, protected IP, and valuable partnerships, we envision a better tomorrow for millions of IBD patients worldwide, and the creation of a wide range of exosome-based nutritional products for a variety of medical conditions.
Prof. Shimon Reif, MD, Chief Medical Advisor & Co-Founder
Pediatric Gastroenterology and head of Department of Pediatrics at Hadassah Medical Center. The author of more than 100 scientific articles in the field of liver and gastrointestinal diseases in children.
Yaffa Elbaum Shiff, PhD, COO & Co-Founder
15 years of experience in Pediatric Nutrition and medical nutrition. Her research focuses on the biological effects of milk exosomes in human and other mammalian milk. Experienced advisor to the food industry.
Golan-Gerstl, PhD, CTO & Co-Founder
Senior Lecturer and Director of the Pediatric Laboratory at the Hadassah Medical Center. Her research focus on milk-derived extracellular vesicles and their miRNA cargo.
Netta Granot, CEO & Co-founder
20 years of experience leading technological, R&D, and innovation teams within the food industry with expertise in infant nutrition plant-based proteins and dairy.
The Market Opportunity
The first target market is medical foods, with a specific focus on Inflammatory Bowel Diseases (IBD) treatment. The global market for medical foods was valued at $23B billion in 2023 and is projected to grow at a CAGR of 5.1% until 2030, within gastrointestinal disorders segment is expected to grow at the faster pace than other segments. The IBD treatment market is valued at $20.3B and is projected to grow at a CAGR of 3.6% until 2030.
Presently, there are 10 million IBD patients worldwide, mostly in North America, Europe, and China, and this number is increasing by 1.5% each year.
